Cost per median overall survival month for abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Pilon, Dominic
Lefebvre, Patrick
Queener, Marykay
Ellis, Lorie
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16080
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [32] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Takashi Kawahara
    Yusuke Saigusa
    Shuko Yoneyama
    Masashi Kato
    Ippei Kojima
    Hiroshi Yamada
    Osamu Kamihira
    Kenichi Tabata
    Hideyasu Tsumura
    Masatsugu Iwamura
    Kazuhide Makiyama
    Hiroji Uemura
    Yasuhide Miyoshi
    BMC Cancer, 23
  • [33] Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
    Kawahara, Takashi
    Saigusa, Yusuke
    Yoneyama, Shuko
    Kato, Masashi
    Kojima, Ippei
    Yamada, Hiroshi
    Kamihira, Osamu
    Tabata, Kenichi
    Tsumura, Hideyasu
    Iwamura, Masatsugu
    Makiyama, Kazuhide
    Uemura, Hiroji
    Miyoshi, Yasuhide
    BMC CANCER, 2023, 23 (01)
  • [34] Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 804 - 804
  • [35] Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 800 - 801
  • [36] PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
    Espana, Sofia
    de Olza, Maria Ochoa
    Sala, Nuria
    Piulats, Josep Maria
    Ferrandiz, Ulises
    Etxaniz, Olatz
    Heras, Lucia
    Buisan, Oscar
    Pardo, Juan Carlos
    Suarez, Jose F.
    Barretina, Pilar
    Comet, Josep
    del Muro, Xavier Garcia
    Sumoy, Lauro
    Font, Albert
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 10251 - 10260
  • [37] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [38] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Giuseppe L. Banna
    Valeria Urzia
    Chiara Benanti
    Alessandra Pitrè
    Helga Lipari
    Rosario Di Quattro
    Ugo De Giorgi
    Giuseppe Schepisi
    Umberto Basso
    Davide Bimbatti
    Francesco Rundo
    Massimo Libra
    Lorenzo Malatino
    Supportive Care in Cancer, 2020, 28 : 4687 - 4695
  • [39] Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
    Banna, Giuseppe L.
    Urzia, Valeria
    Benanti, Chiara
    Pitre, Alessandra
    Lipari, Helga
    Di Quattro, Rosario
    De Giorgi, Ugo
    Schepisi, Giuseppe
    Basso, Umberto
    Bimbatti, Davide
    Rundo, Francesco
    Libra, Massimo
    Malatino, Lorenzo
    SUPPORTIVE CARE IN CANCER, 2020, 28 (10) : 4687 - 4695
  • [40] Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
    Zhang, Wei
    Wu, Teng-Yun
    Chen, Qi
    Shi, Xiao-Lei
    Xiao, Guang-An
    Zhao, Lin
    Xu, Chuan-Liang
    Zhou, Tie
    Sun, Ying-Hao
    ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (02) : 196 - 202
12345